Back to results
US 11,173,165 B2Granted
Optimizing mifepristone levels for Cushing's patients
AssigneeCorcept Therapeutics, Inc.
InventorsJoseph Belanoff, Coleman Gross
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing's syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.
Claims15
A method of treating hypercortisolism in a patient, the method comprising:
- administering an initial daily dose of mifepristone once daily for at least seven days, wherein said initial daily dose is a dose selected from 300 milligrams (mg), 600 mg, and 900 mg of mifepristone;
- adjusting the dose amount of mifepristone to provide an adjusted daily dose of mifepristone if the plasma mifepristone level of the patient is less than 1631 ng/mL after administration of said at least seven days of administration of the initial daily dose of mifepristone, wherein said adjusted daily dose is a dose selected from 600 mg, 900 mg, and 1200 mg of mifepristone wherein said adjusting is performed in order to achieve a mifepristone plasma level of at least 1631 ng/mL;
- and
- administering to the patient said adjusted daily dose of mifepristone,
- thereby achieving a mifepristone plasma level of at least 1631 ng/mL
- with the proviso that the patient is not already suffering from a condition indicated for treatment with mifepristone,
- thereby treating hypercortisolism in the patient by achieving a mifepristone plasma level of at least 1631 ng/mL.
4 more elements
Dependencies are inferred from the claim text.